About Lifitegrast API
Therapeutic CategoryOpthamology
CAS Number
1025967-78-5
API Technology
Synthetic
Dose Form
Opthalmic
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF
Mechanism of Action
Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in dry eye disease is not known
Indication
Xiidra (lifitegrast ophthalmic solution) 5% is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED).
Related APIs
Perfluorohexyloctane
Opthamology
Lifitegrast
Opthamology
Travoprost
Opthamology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Lifitegrast is used to treat the signs and symptoms of dry eye disease (keratoconjunctivitis sicca).
-
Ophthalmic solution, 50 mg/mL (5%)
-
Store at 20°C to 25°C (68°F to 77°F)
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.